The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India
Open accessAbstract
Hypertension is a major public health challenge in low- and middle-income countries (LMICs) and calls for large-scale effective hypertension control programs. Adoption of drug and dose-specific treatment protocols recommended by the World Health Organization-HEARTS Initiative is key for hypertension control programs in LMICs. We estimated the annual medication cost per patient using three such protocols (protocol-1 and protocol-2 with Amlodipine, Telmisartan, using add-on doses and different drug orders, adding Chlorthalidone; protocol-3 with a single-pill combination (SPC) of Amlodipine/Telmisartan with dose up-titration, and addition of Chlorthalidone, if required) in India. The medication cost was simulated with different hypertension control assumptions for each protocol and calculated based on prices in the public and private sectors in India. The estimated annual medication cost per patient for protocol-1 and protocol-2 was $33.88–58.44 and $51.57–68.83 for protocol-3 in the private sector. The medication cost was lower in the generic stores ($5.78–9.57 for protocol-1 and protocol-2, and $7.35–9.89 for protocol-3). The medication cost for patients was the lowest ($2.05–3.89 for protocol-1 and protocol-2, and $2.94–3.98 for protocol-3) in the public sector. At less than $4 per patient per annum, scaling up a hypertension control program with specific treatment protocols is a potentially cost-effective public health intervention. Expanding low-cost generic retail networks would extend affordability in the private sector. The cost of treatment with SPC is comparable with non-SPC protocols and can be adopted in a public health program considering the advantage of simplified logistics, reduced pill burden, improved treatment adherence, and blood pressure control.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L., Jones, D. W., Materson, B. J., Oparil, S., Wright, J. T., et al. (2003) · Hypertension · doi:10.1161/01.hyp.0000107251.49515.c2 · Cited by 13,271
A Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Olsen, M. H., Angell, S. Y., Asma, S., Boutouyrie, P., Burger, D., Chirinos, J. A., Damasceno, A., Delles, C., Gimenez-Roqueplo, A.-P., Hering, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31134-5 · Cited by 939
Self-citationEmerging trends in hypertension epidemiology in India
Gupta, R., Gaur, K., & S. Ram, C. V. (2019) · Journal of Human Hypertension · doi:10.1038/s41371-018-0117-3 · Cited by 269 · cited 1×
“INTRODUCTION In India more than 200 million adults have hypertension, but less than one-tenth of the hypertensive population have their blood pressure (BP) controlled [1, 2].”
BackgroundPrenissl, J., Manne-Goehler, J., Jaacks, L. M., Prabhakaran, D., Awasthi, A., Bischops, A. C., Atun, R., Bärnighausen, T., Davies, J. I., Vollmer, S., et al. (2019) · PLOS Medicine · doi:10.1371/journal.pmed.1002801 · Cited by 226 · cited 1×
“INTRODUCTION In India more than 200 million adults have hypertension, but less than one-tenth of the hypertensive population have their blood pressure (BP) controlled [1, 2].”
BackgroundHypertension: The most important non communicable disease risk factor in India
Gupta, R., & Xavier, D. (2018) · Indian Heart Journal · doi:10.1016/j.ihj.2018.02.003 · Cited by 190 · cited 1×
“6 million deaths annually in India, mostly due to ischemic heart disease and stroke [3].”
Backgroundvan Mourik, M. S., Cameron, A., Ewen, M., & Laing, R. O. (2010) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-10-25 · Cited by 180
Indian guidelines on hypertension-IV (2019)
Shah, S. N., Munjal, Y. P., Kamath, S. A., Wander, G. S., Mehta, N., Mukherjee, S., Kirpalani, A. L., Gupta, P., Shah, H., Rohatgi, R., et al. (2020) · Journal of Human Hypertension · doi:10.1038/s41371-020-0349-x · Cited by 144 · cited 1×
“However, despite their recommendation in the national hypertension treatment guidelines [22] and abundant availability in the Indian market [23], there is limited availability of antihypertensive SPC drugs in the public health sector as India has not yet included antihypertensive SPC medications in the National EML [2…”
BackgroundProtocol-Based Treatment of Hypertension: A Critical Step on the Pathway to Progress
Frieden, T. R., King, S. M. C., & Wright, J. S. (2013) · JAMA · doi:10.1001/jama.2013.282615 · Cited by 79
Research works printed but not linked: 1
- Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. J Hypertens [Internet]. 2018;36:1956–2041. https://pubmed.ncbi.nlm.nih.gov/30234752/. Accessed 26 Jan 2022.
Cited by
Hypertension Diagnosis, Treatment, and Control in India
Varghese, J. S., Venkateshmurthy, N. S., Sudharsanan, N., Jeemon, P., Patel, S. A., Thirumurthy, H., Roy, A., Tandon, N., Narayan, K. M. V., Prabhakaran, D., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.39098 · Cited by 126
Global health 2050: the path to halving premature death by mid-century
Jamison, D. T., Summers, L. H., Chang, A. Y., Karlsson, O., Mao, W., Norheim, O. F., Ogbuoji, O., Schäferhoff, M., Watkins, D., Adeyi, O., et al. (2024) · The Lancet · doi:10.1016/s0140-6736(24)01439-9 · Cited by 125
Frieden, T. R., Garg, R., Moran, A. E., & Whelton, P. K. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00561-6 · Cited by 23
Self-citationKaur, P., Sakthivel, M., Venkatasamy, V., Jogewar, P., Gill, S. S., Kunwar, A., Sharma, M., Pathni, A. K., Durgad, K., Sahoo, S. K., et al. (2024) · Global Heart · doi:10.5334/gh.1305 · Cited by 22
“In the two states, the difference in cost between the regimens was substantial: Using amlodipine in the first two steps reduced the cost by about 20% (2.05 US$ vs. 2.50 US$) per patient treated per year [27].”
BackgroundInfluentialSelf-citationSatheesh, G., Dhurjati, R., Huffman, M. D., Rosende, A., Rodgers, A., Prabhakaran, D., Ordúñez, P., Jha, V., & Salam, A. (2023) · Journal of Hypertension · doi:10.1097/hjh.0000000000003636 · Cited by 21
Metadata
- Authors
- Sahoo, S. K., Pathni, A. K., Krishna, A., Sharma, B., Cazabon, D., Moran, A. E., & Hering, D.
- Affiliations
- Resolve to Save Lives (US)
- Columbia University Irving Medical Center (US)
- Gdańsk Medical University (PL)
- Corresponding author
- Hering, Dagmara
- ORCID
- Venue
- Journal of Human Hypertension
- Published
- 2022-10-21
- Volume
- 37
- Issue
- 9
- Pages
- 828-834
- ISSN
- 0950-9240 (ISSN-L)
- 1476-5527
- PMC
- PMC10471490
- OpenAlex
- W4307090199
- Cited by
- 18
- References
- 17
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 5 · 2023: 3 · 2022: 1
- FWCI
- 2.44
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Journal of Human Hypertension (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Funders
- Resolve to Save Lives
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Healthcare Systems and Reforms
- Keywords
- antihypertensive therapy, drug costs, treatment protocols, amlodipine, telmisartan, chlorthalidone, single-pill combination, generic drug prices, public and private health sectors, hypertension control program, cost-effectiveness, India
- MeSH terms
- Telmisartan, Chlorthalidone, Humans, Hypertension, India, Private Sector, Amlodipine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. https://app.cochat.ai/papers/10.1038/s41371-022-00766-x
- The paper
- Sahoo, S. K., Pathni, A. K., Krishna, A., Sharma, B., Cazabon, D., Moran, A. E., & Hering, D. (2022). Financial implications of protocol-based hypertension treatment: an insight into medication costs in public and private health sectors in India. Journal of Human Hypertension. https://doi.org/10.1038/s41371-022-00766-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.